Fox Run Management L.L.C. Lowers Position in ADMA Biologics Inc $ADMA

Fox Run Management L.L.C. lowered its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 26.0% during the second quarter, HoldingsChannel.com reports. The firm owned 25,373 shares of the biotechnology company’s stock after selling 8,933 shares during the period. Fox Run Management L.L.C.’s holdings in ADMA Biologics were worth $462,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Invesco Ltd. grew its stake in shares of ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock valued at $255,279,000 after buying an additional 1,570,649 shares during the period. Nuveen LLC acquired a new position in ADMA Biologics in the first quarter valued at $93,543,000. American Century Companies Inc. grew its position in ADMA Biologics by 12.7% during the first quarter. American Century Companies Inc. now owns 4,252,362 shares of the biotechnology company’s stock valued at $84,367,000 after acquiring an additional 478,800 shares during the period. Allspring Global Investments Holdings LLC increased its stake in ADMA Biologics by 8.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 3,320,251 shares of the biotechnology company’s stock worth $59,366,000 after acquiring an additional 271,305 shares during the last quarter. Finally, Driehaus Capital Management LLC raised its holdings in shares of ADMA Biologics by 114.9% in the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock worth $58,460,000 after purchasing an additional 1,575,363 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $16.03 on Wednesday. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The company has a market capitalization of $3.83 billion, a price-to-earnings ratio of 18.64 and a beta of 0.40. The firm’s fifty day moving average price is $15.30 and its 200 day moving average price is $17.74.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. During the same period in the prior year, the company posted $0.15 EPS. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $28.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.